{"entity":{"id":"nct07723482","kind":"trial","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","aka":[],"tldr":"A phase 1/2 trial in lung cancer, run by BrYet US, Inc., not yet recruiting.","summary":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement is a phase 1/2, interventional study registered as NCT07723482 by BrYet US, Inc., with a registry enrolment figure of 108 participants, started 2026-08 and due to reach its primary completion in 2027-08. Interventions recorded: ML-016. Conditions listed: Advanced Solid Tumor With Lung and/or Liver Involvement. Primary outcome: Incidence of dose-limiting toxicities (DLTs) during the DLT assessment period; Frequency and severity of adverse events (AEs) and serious AEs (SAEs); Maximum tolerated dose (MTD) and doses recommended for expansion. Lung eligibility wording from the registry: \"Evidence of tumor in the lung and/or liver based on imaging studies\". Sites: Australia. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07723482","url":"https://clinicaltrials.gov/study/NCT07723482"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07723482","phase":"1/2","setting":"Phase 1/2 Study of ML-016 in Participants With Advanced Cancer With Lung and/or Liver Involvement","sponsor":"BrYet US, Inc.","enrolled":108,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07723482/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}